Oxaliplatin (3 months <i>v</i> 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07.

J Clin Oncol · 2022 · PMC9671755 · PMID 35772045

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

16 However, in the SCOT study, 3 months of treatment showed a favorable trend for DFS in high-risk stage II disease. 15 These discordant findings in high-risk stage II disease may be due to different sample sizes and chemotherapy regimens among studies.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.